Sonova Holding (OTCMKTS:SONVY) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Sonova Holding (OTCMKTS:SONVY) have been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, one has issued a buy recommendation and two have assigned a strong buy recommendation to the company.

A number of brokerages recently commented on SONVY. Morgan Stanley upgraded Sonova from an “underweight” rating to an “equal weight” rating in a research report on Tuesday, June 23rd. Citigroup reiterated a “sell” rating on shares of Sonova in a research report on Wednesday, May 13th. BNP Paribas Exane upgraded Sonova from a “strong sell” rating to a “strong-buy” rating in a research report on Tuesday, March 10th. Finally, Jefferies Financial Group lowered Sonova from a “hold” rating to a “moderate sell” rating in a research report on Wednesday, March 18th.

Sonova Stock Down 0.2%

Shares of OTCMKTS:SONVY opened at $47.93 on Friday. Sonova has a twelve month low of $42.26 and a twelve month high of $61.10. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.43 and a current ratio of 1.75. The business has a fifty day moving average of $48.59 and a 200-day moving average of $49.88.

Sonova Company Profile

Sonova AG (OTCMKTS:SONVY) is a Switzerland-based provider of hearing care solutions, headquartered in Stäfa. The company designs, develops, manufactures and distributes a range of audiological products and related services aimed at improving hearing and communication for people with hearing loss. Its portfolio spans behind-the-ear and in-the-ear hearing instruments, wireless accessories and software solutions that enable connectivity with consumer devices and audiological fittings.

Sonova markets its products under several well-known brands, including Phonak and Unitron for hearing aids, and it is also associated with Advanced Bionics for cochlear implant systems.